Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).
JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. 2023 S. TPS484-TPS484
Erscheinungsjahr: 2023
Publikationstyp: Zeitschriftenaufsatz
| Geprüft | Bibliothek |
Autoren
Lee, Keun-Wook (Autor)
Moehler, Markus H. (Autor)
Cunningham, David (Autor)
Wainberg, Zev A. (Autor)
Uronis, Hope Elizabeth (Autor)
Oh, Do-Youn (Autor)
Kim, In-Ho (Autor)
Shim, Byoung Yong (Autor)
Sym, Sun Jin (Autor)
Altura, Rachel A. (Autor)
Stilian, Melissa C. (Autor)
Parker, Elizabeth C. (Autor)
Klempner, Samuel J. (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
